database > company
Computerized Thermal Imaging
Medical Devices & Tech
1719 W. 2800 South
Ogden, UT 84401 USA
phone:801-776-4700
fax:801-459-6063
Symbol COIB
Exchange .PK
Founded 1987
Employees 6
          www.cti-net.com
Research Sector Medical Devices & Tech
Summary Description
Thermal imaging systems and infrared devices.
Management
Richard V. Secord, Chairman and CEO
Ownership
Financials


* numbers in thousands
 
Keywords
thermal imaging, infrared, breast, breast lesions, blood, circulation, diagnostics, breast cancer, physiological, infrared, imaging, pain management, PainManagement


Comment | Printable Version | Modify profile Mar. 01, 2010

Description
Computerized Thermal Imaging (CTI) develops, manufactures and markets thermal imaging systems for clinical diagnosis and pain management.
Products / Services
CTI markets two FDA-cleared pain management products: a diagnostic Thermal Imaging Processor (TIP) and an infrared light therapy device called the Photonic Stimulator.
Technology / Differentiation
CTI's systems are based on computerized interpretations of thermal photography using proprietary software. The Photonic Stimulator emits infrared light that penetrates the skin in an effort to promote increased blood flow and circulation to provide temporary relief of minor aches and pains. TIP is used to develop a physiological profile of a patient to assist in the diagnosis and treatment of a range of physiological and circulatory abnormalities, principally soft-tissue related injuries and pain. The BCS 2100 provides a noninvasive method to collect information for the evaluation of suspicious breast lesions.
Market / Customers
The company's target customers include hospital radiology departments, cancer research facilities and imaging centers, chiropractors and physical therapists, and manufacturers of products with complex cast components or processes.
Strategy
The company's key stratgey is to get a pre-market approval for its BCS 2100, a breast imaging system that assist radiologists in their efforts to distinguish between benign and malignant breast masses. The FDA rejected the company's application for pre-market approval of the BCS 2100 in January 2003.
Status
Due to financial limitations the company has substantially curtained its operations, including manufacturing, research and development, sales and marketing and regulatory compliance activities.


2010-03-08-1422